Group 1 - The stock of Luye Pharma Group (博安生物) increased by nearly 5%, reaching HKD 9.12 with a trading volume of HKD 358 million as of the report time [1] - On January 21, Luye Pharma announced that its board was informed by its controlling shareholder, Luye Pharma Group, about a plan to transfer 38.5 million H-shares to the market through its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., on January 22, 2026 [1] - Luye Pharma previously acquired 98% of the shares of Luye Geneora Holding Limited, integrating its antibody drug pipeline, technology platform, and production assets, with Shandong Luye Pharmaceutical Co., Ltd. becoming the core holding entity [1] Group 2 - By 2025, Shandong Luye Pharmaceutical Co., Ltd. is expected to hold 70.81% of Luye Pharma's shares [1] - Luye Pharma serves as a key vehicle for Luye Pharma Group's transition from traditional small molecules to biopharmaceuticals, aiding in the establishment of a dual research and development system for "chemical drugs + biological drugs" [1]

Core Viewpoint - Luye Pharma Group's subsidiary, Shandong Luye Pharmaceutical Co., plans to transfer 38.5 million H-shares of Boan Biotechnology by January 22, 2026, as part of a subscription agreement related to exchangeable preferred shares [1] Group 1: Company Developments - Boan Biotechnology's stock rose nearly 5%, trading at HKD 9.12 with a transaction volume of HKD 358 million [1] - Luye Pharma previously acquired 98% of Boan Biotechnology, integrating its antibody drug pipeline, technology platform, and production assets [1] - By 2025, Shandong Luye Pharmaceutical will hold 70.81% of Boan Biotechnology's shares, positioning Boan as a key vehicle for Luye Pharma's transition from traditional small molecules to biopharmaceuticals [1] Group 2: Strategic Importance - Boan Biotechnology plays a crucial role in Luye Pharma's dual-line R&D system, combining chemical and biopharmaceutical development [1]

Group 1 - The company Boan Biotechnology (06955) announced that its board has been informed by its controlling shareholder, Luye Pharma Group, regarding a subscription agreement related to exchangeable preferred shares [1] - Luye Pharma's wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., is set to transfer 38.5 million H-shares to the issuer, Luye Geneora Holding Limited, on January 22, 2026, as part of the proposed transfer [1]

Core Viewpoint - The company Boan Biotechnology (06955) announced that its board has been informed by its controlling shareholder, Luye Pharmaceutical Group, regarding a proposed transfer of 38.5 million H-shares by its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to the issuer Luye Geneora Holding Limited on January 22, 2026 [1] Group 1 - The controlling shareholder, Luye Pharmaceutical Group, is involved in a share transfer agreement related to exchangeable preferred shares [1] - The proposed transfer involves a significant number of shares, specifically 38.5 million H-shares [1] - The transaction is scheduled to take place on January 22, 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 自願性公告 控股股東轉讓股份 本公告由 山東博安生物技術 股份有限公司（「本公司」）自 願 刊 發。 茲提述本公司日期為2026年1月11日之公告（「該公告」），內 容 有 關（其 中 包 括）本 公司控股股東 綠葉製藥集團有限公司（「綠葉製藥」，連 同 其 附 屬 公 司 統 稱「綠 葉 製藥集團」）擬轉讓本公司股本中之H股（「擬議轉讓」）。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 該 公 告 所 界 定 者 具 有 相 同 涵 義。 本公司董事會（「董事會」）已 獲 綠 葉 製 藥 集 團 知 會，根 據 與 ...

Core Viewpoint - The company, Bohan Bio (06955), has entered into a financing lease agreement with Industrial Bank Leasing, which is expected to enhance its working capital and support its strategic goals through a more balanced and efficient financing structure [1] Group 1: Financing Lease Agreement - The financing lease agreement is set to commence on January 14, 2026, where Industrial Bank Leasing will purchase leasing assets from the company and lease them back during the lease term [1] - The leased assets consist of various machinery and equipment [1] - The agreement includes provisions for early termination based on its terms and conditions [1] Group 2: Strategic Implications - The board believes that the financing lease agreement will strengthen the company's operational funding situation [1] - It aims to facilitate both short-term and long-term financing strategies, thereby supporting current and future business operations and market activities [1] - The agreement is aligned with the company's strategic objectives [1]

Core Viewpoint - The company has entered into a financing lease agreement with Industrial Bank Leasing, which is expected to enhance its working capital and support its strategic goals through a more balanced and efficient financing structure [1] Group 1 - The financing lease agreement is set to commence on January 14, 2026 [1] - The leased assets consist of various machinery and equipment [1] - The agreement allows for early termination based on its terms and conditions [1] Group 2 - The board believes that the financing lease will strengthen the company's operational funding situation [1] - The agreement aims to support both current and future business operations and market activities [1] - The financing structure is intended to achieve a more balanced and efficient long-term and short-term financing portfolio [1]

Core Viewpoint - The company, 博安生物 (06955.HK), has entered into a financing lease agreement with 兴业金租, which involves the purchase and leasing of certain machinery and equipment [1] Group 1 - The financing lease agreement is set to commence on January 14, 2026 [1] - 兴业金租 will purchase the leasing assets from the company and lease them back during the lease term [1] - The agreement includes provisions that allow for early termination based on its terms and conditions [1]

（股 份 代 號：6955） 自願性公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Shandong Boan Biotechnology Co., Ltd. 融資租賃協議 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 於2026年1月14日，本 公 司 與 興 業 金 租 訂 立 融 資 租 賃 協 議，據 此，興 業 金 租 將 自 本 公 司 購 買 租 賃 資 產 並 將 於 租 賃 期 內 向 本 公 司 出 租 該 租 賃 資 產，惟 可 根 據 融 資 租 賃 協 議 的 條 款 及 條 件 提 早 終 止。 融資租賃協議 於2026年1月14日，本 公 司 與 興 業 金 租 訂 立 融 資 租 賃 協 議，據 此，興 業 金 租 將 自 本 公 司 購 買 租 賃 資 產 並 將 於 租 賃 期 內 向 本 ...

Core Viewpoint - The article highlights the recent developments of BGI Biotechnology (博安生物), including a significant shareholder transfer and the approval of its biosimilar drug BA6101 in Bolivia [1]. Group 1: Shareholder Activity - On January 13, BGI Biotechnology's shareholders transferred stocks from China Securities Registration and Clearing Hong Kong to CITIC Securities Brokerage Hong Kong, with a market value of HKD 512 million, accounting for 8.76% of the total shares [1]. Group 2: Product Approval - On January 13, BGI Biotechnology announced that its self-developed drug BA6101 (60mg) has been approved for market release by Bolivia's National Medicines and Health Technologies Agency (AGEMED) [1]. - BA6101 is a biosimilar referencing the original drug Prolia®, which is widely used globally for the treatment of osteoporosis [1].